SCPH

scPharmaceuticals Inc. [SCPH] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SCPH Stock Summary

Top SCPH Correlated Resources

SCPH

Top 10 Correlated ETFs

SCPH

Top 10 Correlated Stocks

SCPH

In the News

SCPH Financial details

Company Rating
-
Market Cap
177.75M
Income
-56.43M
Revenue
13.59M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
135
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-4.65
Forward P/E
-
PEG
-4.09
P/S
30.04
P/B
4.95
P/C
-
P/FCF
-4.03
Quick Ratio
8.62
Current Ratio
9.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.47
EPS next Y
-
EPS next Q
-
EPS this Y
7.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
60.59%
EPS Q/Q
-10%
-
-
-
-
SMA20
61.66%
SMA50
48.73%
SMA100
21.36%
Inst Own
-
Inst Trans
-
ROA
-49%
ROE
31%
ROC
-0.52%
Gross Margin
73%
Oper. Margin
-662%
Profit Margin
-699%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.63-12.75
52W High
-67.08%
52W Low
-1.25%
RSI
62.44
Rel Volume
0.9
Avg Volume
235.01K
Volume
211.1K
Perf Week
-4.13%
Perf Month
56.13%
Perf Quarter
25.8%
Perf Half Y
16.18%
-
-
-
-
Beta
0.045
-
-
Volatility
0.11%, 0.68%
Prev Close
-1.25%
Price
3.95
Change
-2.71%

Something similar

Top by Market Cap
FB2A.DE
TSLA
NVDA
MSF.DE
BRK-B
Top Correlated ETFs
PSIL
ROX.DE
EFA
VEA
IEFA
Top Correlated Stocks
000668.SZ
ECL
ASM
ASM.TO
GEG
Similar Market Cap
RAANX
HSFNX
HSTC.L
LYBC
0643.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 235.01K
  • Market Capitalization 177.75M
  • Employee 135
  • CEO Mr. John H. Tucker
  • Headquarters Burlington,MA,US
  • IPO Date 2017-11-17
  • Website https://www.scpharmaceuticals.com

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.